JP2019517507A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019517507A5 JP2019517507A5 JP2018563067A JP2018563067A JP2019517507A5 JP 2019517507 A5 JP2019517507 A5 JP 2019517507A5 JP 2018563067 A JP2018563067 A JP 2018563067A JP 2018563067 A JP2018563067 A JP 2018563067A JP 2019517507 A5 JP2019517507 A5 JP 2019517507A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- amino acid
- acid sequence
- vegfr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 239000003795 chemical substances by application Substances 0.000 claims 8
- 206010001150 Adenocarcinoma gastric Diseases 0.000 claims 6
- 201000007492 gastroesophageal junction adenocarcinoma Diseases 0.000 claims 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 5
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 5
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 5
- 201000009036 biliary tract cancer Diseases 0.000 claims 4
- 208000020790 biliary tract neoplasm Diseases 0.000 claims 4
- 208000023747 urothelial carcinoma Diseases 0.000 claims 4
- 230000000750 progressive effect Effects 0.000 claims 2
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021059858A JP7372955B2 (ja) | 2016-06-03 | 2021-03-31 | 特定の癌の治療のためのラムシルマブとペンブロリズマブとの組み合わせ |
| JP2022151872A JP2022184998A (ja) | 2016-06-03 | 2022-09-22 | 特定の癌の治療のためのラムシルマブとペンブロリズマブとの組み合わせ |
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662345322P | 2016-06-03 | 2016-06-03 | |
| US62/345,322 | 2016-06-03 | ||
| US201662377852P | 2016-08-22 | 2016-08-22 | |
| US62/377,852 | 2016-08-22 | ||
| US201662398663P | 2016-09-23 | 2016-09-23 | |
| US62/398,663 | 2016-09-23 | ||
| US201662434466P | 2016-12-15 | 2016-12-15 | |
| US62/434,466 | 2016-12-15 | ||
| US201762460404P | 2017-02-17 | 2017-02-17 | |
| US62/460,404 | 2017-02-17 | ||
| US201762469670P | 2017-03-10 | 2017-03-10 | |
| US62/469,670 | 2017-03-10 | ||
| PCT/US2017/034732 WO2017210119A1 (en) | 2016-06-03 | 2017-05-26 | Combination of ramucirumab and pembrolizumab for the treatment of certain cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021059858A Division JP7372955B2 (ja) | 2016-06-03 | 2021-03-31 | 特定の癌の治療のためのラムシルマブとペンブロリズマブとの組み合わせ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019517507A JP2019517507A (ja) | 2019-06-24 |
| JP2019517507A5 true JP2019517507A5 (https=) | 2019-07-25 |
Family
ID=59067893
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018563067A Withdrawn JP2019517507A (ja) | 2016-06-03 | 2017-05-26 | 特定の癌の治療のためのラムシルマブとペンブロリズマブとの組み合わせ |
| JP2021059858A Active JP7372955B2 (ja) | 2016-06-03 | 2021-03-31 | 特定の癌の治療のためのラムシルマブとペンブロリズマブとの組み合わせ |
| JP2022151872A Withdrawn JP2022184998A (ja) | 2016-06-03 | 2022-09-22 | 特定の癌の治療のためのラムシルマブとペンブロリズマブとの組み合わせ |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021059858A Active JP7372955B2 (ja) | 2016-06-03 | 2021-03-31 | 特定の癌の治療のためのラムシルマブとペンブロリズマブとの組み合わせ |
| JP2022151872A Withdrawn JP2022184998A (ja) | 2016-06-03 | 2022-09-22 | 特定の癌の治療のためのラムシルマブとペンブロリズマブとの組み合わせ |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20190183972A1 (https=) |
| EP (1) | EP3463456A1 (https=) |
| JP (3) | JP2019517507A (https=) |
| WO (1) | WO2017210119A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| PE20200859A1 (es) | 2017-06-02 | 2020-08-25 | Bayer Healthcare Llc | Combinacion farmaceutica que comprende regonafenib y nivolumab como anticancerigeno |
| CN112543646B (zh) * | 2018-11-06 | 2023-11-14 | 江苏恒瑞医药股份有限公司 | 一种抗pd-1抗体和法米替尼联合在制备治疗肿瘤的药物中的用途 |
| EP3893902B1 (en) | 2018-12-11 | 2024-10-23 | Sanford Burnham Prebys Medical Discovery Institute | Inhibitors of pd-l1 activity or expression for use in the treatment of serrated colorectal cancer |
| KR20230087451A (ko) * | 2020-09-02 | 2023-06-16 | 주식회사 파멥신 | 암 환자를 치료하기 위한 pd-1 길항제 및 vegfr-2에 대한 길항제의 조합 요법 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1916001T1 (sl) | 2002-03-04 | 2011-10-28 | Imclone Llc | Äśloveĺ ka protitelesa specifiäśna za kdr in njihova uporaba |
| US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| TW201622744A (zh) * | 2014-03-04 | 2016-07-01 | 美國禮來大藥廠 | 癌症之組合療法 |
| JP2017515859A (ja) * | 2014-05-15 | 2017-06-15 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｐｄ−１抗体と他の抗癌剤の組み合わせを使用する肺癌の処置 |
| AU2015327868A1 (en) * | 2014-10-03 | 2017-04-20 | Novartis Ag | Combination therapies |
-
2017
- 2017-05-26 US US16/305,327 patent/US20190183972A1/en not_active Abandoned
- 2017-05-26 WO PCT/US2017/034732 patent/WO2017210119A1/en not_active Ceased
- 2017-05-26 JP JP2018563067A patent/JP2019517507A/ja not_active Withdrawn
- 2017-05-26 EP EP17730608.1A patent/EP3463456A1/en not_active Withdrawn
-
2021
- 2021-03-31 JP JP2021059858A patent/JP7372955B2/ja active Active
-
2022
- 2022-09-22 JP JP2022151872A patent/JP2022184998A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019517507A5 (https=) | ||
| CY1121735T1 (el) | 7-benzyλ-10-(2-meθyλobenzyλ)-2,6,7,8,9,10-eξaϋδpoϊmiδazo[1,2-α]πυριδο[4,3-d]πυριμιδιν-5(3η)-ονη για χρηση στην αγωγη του καρκινου | |
| EA201990979A1 (ru) | Способы лечения рака желудочно-кишечного тракта с применением комбинационных видов терапии, содержащих липосомальный иринотекан и оксалиплатин | |
| CN112888458A (zh) | Cldn18的抗体和化疗药物的联合治疗 | |
| JP2016530280A5 (https=) | ||
| JP2017501155A5 (https=) | ||
| JP2016528162A5 (https=) | ||
| WO2017062619A3 (en) | Combination therapy for the treatment of cancer | |
| JP2018522028A5 (https=) | ||
| HRP20230523T1 (hr) | Antitumorski agens i sredstvo za poboljšavanje antitumorskog efekta | |
| JP2017527582A5 (https=) | ||
| WO2017062615A3 (en) | Combination therapy for the treatment of cancer | |
| RU2018127640A (ru) | Комбинация ингибитора hdac и антитела против pd-l1 для лечения рака яичников | |
| JP2017516827A5 (https=) | ||
| JP2016526021A5 (https=) | ||
| JP2021505669A5 (https=) | ||
| MX2021014523A (es) | Metodos para tratar colangiocarcinoma. | |
| RU2015145948A (ru) | Противоопухолевый агент, включающий гидрат гидрохлорида иринотекана | |
| HRP20211709T1 (hr) | Antitumorski lijek koji sadrži antitumorski kompleks platine, i pojačivač antitumorskog efekta | |
| Marinichenko et al. | Combined chemoradiotherapy regimens and their effectiveness in the treatment of patients with non-small-cell unresectable stage III lung cancer: review of literature | |
| Izycka | Carboplatin/paclitaxel | |
| Oguma | Cisplatin/dexamethasone/fluorouracil | |
| Li et al. | Comparison between the effect of SOX regimen and FOLFOX4 regimen for advanced gastric cancer | |
| Takahashi | Lung cancer: progress in diagnosis and treatments. Topics: III. Treatment; 3. Chemotherapy for patients with non-small cell lung cancer, 1) Cytotoxic drug treatment, maintenance therapy, and secondary line treatment | |
| Lee | Current Status of Targeted Therapies in the Treatment of Metastatic Colorectal Cancer |